Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive) or not (HER2-negative). Typically, patients with HER2-positive disease have a worse prognosis. Trastuzumab is a selective treatment that targets the HER2 pathway. The available evidence supporting trastuzumab regimens mostly relies upon surrogate endpoints and, although the efficacy results seem to support its use, other uncertainties have been raised about its net benefit in relation to transient cardiac toxicity and a long-term increased risk of metastasis to the central nervous system.

Trastuzumab-containing regimens for metastatic breast cancer / S. Balduzzi, S. Mantarro, V. Guarneri, L. Tagliabue, V. Pistotti, L. Moja, R. D'Amico. - In: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. - ISSN 1469-493X. - 2014:6(2014 Jun), pp. CD006242.1-CD006242.80.

Trastuzumab-containing regimens for metastatic breast cancer

L. Tagliabue;L. Moja
Penultimo
;
2014

Abstract

Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive) or not (HER2-negative). Typically, patients with HER2-positive disease have a worse prognosis. Trastuzumab is a selective treatment that targets the HER2 pathway. The available evidence supporting trastuzumab regimens mostly relies upon surrogate endpoints and, although the efficacy results seem to support its use, other uncertainties have been raised about its net benefit in relation to transient cardiac toxicity and a long-term increased risk of metastasis to the central nervous system.
Settore MED/06 - Oncologia Medica
Settore MED/42 - Igiene Generale e Applicata
giu-2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
CD006242.pdf

Open Access dal 25/06/2015

Tipologia: Publisher's version/PDF
Dimensione 901.84 kB
Formato Adobe PDF
901.84 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/237345
Citazioni
  • ???jsp.display-item.citation.pmc??? 83
  • Scopus 95
  • ???jsp.display-item.citation.isi??? 149
social impact